A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis

NCT ID: NCT01321359

Last Updated: 2013-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

907 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, two arm, parallel-group, vehicle-controlled, multi-center study of NB-001. The study is designed to demonstrate the safety and efficacy of NB-001 in subjects with RHL. Approximately 850 subjects who meet all eligibility criteria will be randomized in the study. Subjects will begin treatment as soon as they experience the onset of cold sore symptoms. Treatment will be applied 5 times daily, approximately 3-4 hours apart while awake. Treatment will continue until the investigator assesses the primary lesion complex as healed or a maximum of 4 days.

Clinic visits will occur on a daily basis until the investigator determines that the primary lesion complex has healed or a maximum of 15 clinic visits. At daily clinic visits, the investigator will make efficacy assessments of the primary lesion complex; safety and tolerability assessments of NB-001 following topical administration will also be assessed daily. Subjects will make daily assessments of therapy.

At the End of Study, the investigator will make a global assessment of therapy. The subject will make global assessments of therapy and social impact.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Herpes Simplex Labialis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vehicle

Vehicle

Group Type PLACEBO_COMPARATOR

Vehicle versus NB-001

Intervention Type DRUG

Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days

Active

Active NB-001(0.3%)

Group Type ACTIVE_COMPARATOR

Vehicle versus NB-001

Intervention Type DRUG

Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vehicle versus NB-001

Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A Healthy man or woman 18 years of age or older. Women who are pregnant, lactating or may become pregnant may (at the investigator's discretion) be included in the study.
* Have recurrent herpes labialis as defined by a history of three (3) or more cold sore recurrences on the lips and/or skin surrounding the lips in the previous 12 months;
* Have the majority of their cold sore recurrences proceeded by a well defined history of prodromal symptoms.

Exclusion Criteria

* Subjects with severe chronic illness
* Received (within the last 6 months) or receiving chemotherapy;
* Significant skin disease on the face
* Previously received herpes vaccine;
* Active alcohol or drug abuse;
* Prior randomization into any NanoBio study;
* Known allergies to topical creams, ointments or other topical medications.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NanoBio Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Radiant Research, Inc

Chandler, Arizona, United States

Site Status

Radiant Research, Inc

Scottsdale, Arizona, United States

Site Status

ACR-Phase 1, LLC.

Anaheim, California, United States

Site Status

Northern California Research

Sacramento, California, United States

Site Status

Medical Center for Clinical Research

San Diego, California, United States

Site Status

Radiant Research, Inc

Santa Rosa, California, United States

Site Status

Westlake Medical Research

Westlake Village, California, United States

Site Status

Longmont Medical Research Network

Longmont, Colorado, United States

Site Status

Avail Clinical Research, LLC

DeLand, Florida, United States

Site Status

Clinical Study Center

Fort Myers, Florida, United States

Site Status

AGA Clinical Trials

Hialeah, Florida, United States

Site Status

Orlando Clinical Research Center

Orlando, Florida, United States

Site Status

Progressive Medical Research

Port Orange, Florida, United States

Site Status

Radiant Research, Inc

Atlanta, Georgia, United States

Site Status

Advanced Clinical Research

Meridan, Idaho, United States

Site Status

MediSphere Medical Research Center, LLC

Evansville, Indiana, United States

Site Status

Radiant Research, Inc.

Overland Park, Kansas, United States

Site Status

Central Kentucky Research Associates, Inc.

Lexington, Kentucky, United States

Site Status

Michigan Center for Research Corp, DBA Michigan Center for Skin Care Research

Clinton Township, Michigan, United States

Site Status

Radiant Research, Inc.

Edina, Minnesota, United States

Site Status

Pioneer Clinical Research, LLC

Bellevue, Nebraska, United States

Site Status

Regional Clinical Research, Inc.

Endwell, New York, United States

Site Status

Physicians' Research, Inc.

Zanesville, Ohio, United States

Site Status

Westover Heights Clinic

Portland, Oregon, United States

Site Status

Paddington Testing Co, Inc

Philadelphia, Pennsylvania, United States

Site Status

Primary Physicians Research

Pittsburgh, Pennsylvania, United States

Site Status

Radiant Research, Inc

Greer, South Carolina, United States

Site Status

Coastal Carolina Research Center

Mt. Pleasant, South Carolina, United States

Site Status

Clinical Research Associates, Inc.

Nashville, Tennessee, United States

Site Status

J&S Studies, Inc.

College Station, Texas, United States

Site Status

Radiant Research-Dallas North

Dallas, Texas, United States

Site Status

Benchmark Research

Fort Worth, Texas, United States

Site Status

Research Across America

Plano, Texas, United States

Site Status

Intermountain Clinical Research

Draper, Utah, United States

Site Status

New River Valley Research Institute

Christiansburg, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NB-001-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.